Comment on: Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis
Academic Article
Publication Date:
2009
CRIS type:
1.1 Articolo in rivista
Keywords:
Adverse events; MDR-TB; XDR-TB; Acetamides; Anti-Bacterial Agents; Extensively Drug-Resistant Tuberculosis; Humans; Linezolid; Oxazolidinones; Tuberculosis, Multidrug-Resistant
List of contributors:
Sotgiu, G.; Lange, C.; Richardson, M. D.; Matteelli, A.; Centis, R.; Eker, B.; Guenther, G.; Spanevello, A.; Migliori, G. B.
Published in: